MedTrace Logo

An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

NCT01269021 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2016-03-17

No results posted yet for this study

Summary

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid .

Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.

Conditions

  • IgA Nephropathy (IgAN)

Interventions

DRUG

mycophenolate mofetil plus lower dose of Prednisone

MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d

DRUG

Prednisone in full dose

0.8-1mg/kg/d

Sponsors & Collaborators

  • Zhi-Hong Liu, M.D.

    lead OTHER

Principal Investigators

  • Zhihong Liu, Master · Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-10-31
Completion
2014-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01269021 on ClinicalTrials.gov